learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
5 / 801 resultslearn Overview
learn Thymosin Beta 4
learn Stem Cell Factor
learn Neem Oil
natural substance from Neem tree with medicinal and pesticidal properties
Research
5 / 1000+ resultsresearch Prevalence of hormonal and endocrine dysfunction in patients with lichen planopilaris (LPP): A retrospective data analysis of 168 patients
Lichen planopilaris (LPP) is linked to androgen excess, while frontal fibrosing alopecia (FFA) is linked to androgen deficiency.
research Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies
The research found that MRI and certain hormone levels can help tell apart ovarian tumors from hyperthecosis in postmenopausal women, but tissue analysis is still needed for a definite diagnosis.
research Predicting Hair Loss with AI: A Deep Learning Framework Combining Genetic and Scalp Health Data
AI can predict hair loss by analyzing genetic, scalp, and lifestyle data.
research Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients
People with Lichen planopilaris are more likely to have certain autoimmune and endocrine disorders but less likely to have conditions like allergies and diabetes.
research Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases
Certain drugs can cause male infertility, so fertility counseling and sperm preservation are advised.
Community Join
5 / 1000+ resultscommunity The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Has anyone seen the data on this 539% boost breakthrough?
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
community Topical Dutasteride - Non-Hormonal, Side Effect Free 5ARI?
Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.
community Doctor says i shouldn't take fin because its "hormonal"
A user in Turkey was advised by a dermatologist to avoid finasteride due to its hormonal effects and was prescribed minoxidil, shampoo, and vitamins instead. The user is considering seeking another doctor's opinion or buying finasteride directly from a pharmacy.